The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy
Open accessAbstract
Glycogen synthase kinase 3β (GSK3β), a multifunctional serine/threonine kinase found in all eukaryotes, had been initially identified as a key regulator of insulin-dependent glycogen synthesis. It is now known that GSK3β functions in diverse cellular processes including proliferation, differentiation, motility and survival. Aberrant regulation of GSK3β has been implicated in a range of human pathologies including non-insulin-dependent diabetes mellitus, cardiovascular disease, some neurodegenerative diseases, and bipolar disorder. As a consequence, the therapeutic potential of GSK3β inhibitors has become an important area of investigation. However, GSK3β also participates in neoplastic transformation and tumor development. The role of GSK3β in tumorigenesis and cancer progression remains controversial; it may function as a “tumor suppressor” for certain types of tumors, but promotes growth and development for some others. GSK3β also mediates drug sensitivity/resistance in cancer chemotherapy. Therefore, although GSK3β is an attractive therapeutic target for a number of human diseases, its potential impact on tumorigenesis and cancer chemotherapy needs to be carefully evaluated. This mini-review discusses the role of GSK3β in tumorigenesis/cancer progression as well as its modulation of cancer chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AP-1: a double-edged sword in tumorigenesis
Eferl, R., & Wagner, E. F. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1209 · Cited by 2,242
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084
The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
Grimes, C. A., & Jope, R. S. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00011-9 · Cited by 1,423
Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation
Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M.-S., Jin, O., & Woodgett, J. R. (2000) · Nature · doi:10.1038/35017574 · Cited by 1,393
Self-citationThe role of epithelial-mesenchymal transition in cancer pathology
guarino, M., rubino, B., & ballabio, G. (2007) · Pathology · doi:10.1080/00313020701329914 · Cited by 790
Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9128-5 · Cited by 774
Beurel, E., & Jope, R. S. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.07.006 · Cited by 541
The Wnt signaling pathway and its role in tumor development
Lustig, B., & Behrens, J. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0431-0 · Cited by 524
Ding, Q., He, X., Hsu, J.-M., Xia, W., Chen, C.-T., Li, L.-Y., Lee, D.-F., Liu, J.-C., Zhong, Q., Wang, X., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00620-06 · Cited by 393
Young, M. R., Li, J.-J., Rincón, M., Flavell, R. A., Sathyanarayana, B. K., Hunziker, R., & Colburn, N. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9827 · Cited by 382
Cited by
Serrano-Gomez, S. J., Maziveyi, M., & Alahari, S. K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0502-x · Cited by 814
GSK-3 as potential target for therapeutic intervention in cancer
McCubrey, J. A., Steelman, L. S., Bertrand, F. E., Davis, N. M., Sokolosky, M., Abrams, S. L., Montalto, G., D’Assoro, A. B., Libra, M., Nicoletti, F., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2037 · Cited by 508
Activators and inhibitors of NRF2: a review of their potential for clinical development
Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., & Cuadrado, A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9372182 · Cited by 413
Triterpenoids as new promising anticancer drugs
Petronelli, A., Pannitteri, G., & Testa, U. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328330fd90 · Cited by 381
Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy
Wang, W., Nag, S., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106124315 · Cited by 282
Wang, L., Li, J., & Di, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21867 · Cited by 261
Zhong, W., Shahbaz, O., Teskey, G., Beever, A., Kachour, N., Venketaraman, V., & Darmani, N. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115797 · Cited by 253
Bonora, M., & Pinton, P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00302 · Cited by 208
Physiopathology of the Permeability Transition Pore: Molecular Mechanisms in Human Pathology
Bonora, M., Patergnani, S., Ramaccini, D., Morciano, G., Pedriali, G., Kahsay, A., Bouhamida, E., Giorgi, C., Wieckowski, M., & Pinton, P. (2020) · Biomolecules · doi:10.3390/biom10070998 · Cited by 135
Liu, B., Jia, Y., Cao, Y., Wu, S., Jiang, H., Sun, X., Ma, J., Yin, X., Mao, A., & Shang, M. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000445633 · Cited by 75
Datta, K., Suman, S., Kallakury, B. V. S., & Fornace, A. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059295 · Cited by 75
Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires
Conant, G., Ahadian, S., Zhao, Y., & Radisic, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-12048-5 · Cited by 25
Metadata
- Authors
- Luo, J.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 273
- Issue
- 2
- Pages
- 194-200
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2114594254
- Cited by
- 429
- References
- 59
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.